Contact Us Customer Service: 1-844-937-7374
Category: Press Releases
ReShape Lifesciences Inc. announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company’s ENDURE II trial in the European Union. The ENDURE II trial is designed to support CE Marking of the ReShape Vest.
ReShape Lifesciences Inc. today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application regarding the Company’s Gastric Vest System (the “ReShape Vest”).
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented this week at the ObesityWeek 2017 conference in Washington D.C.
According to a report by the U.S. Centers for Disease Control and Prevention (CDC), about 630,000 people in the United States were diagnosed with a cancer associated with being overweight or obese in 2014.